petri dish

Analysis

Life sciences & health care M&A update: Q2 2018

As the importance of obtaining, analyzing, and using data, referred to as real-world data and real-world evidence, in the Life Science and Health Care industry increases, the need to manage this data in-house has grown as well. This Life Sciences & Health Care mergers and acquisitions (M&A) update provides Deloitte Corporate Finance LLC insights and market data analysis that shed light on M&A trends in the Life Sciences and Health Care industry.

Integration trends driving M&A by payors

With real world date (RWD) and real world evidence (RWE) becoming integral in the health care field, M&A for pharmaceuticals saw a rise, as there is a pushed need for digital and electronic health care information management.1

Deloitte RWE benchmarking survey findings2
  • Increasing importance of RWE integration: Many pharmaceutical companies are now leveraging RWD holistically throughout their organizations to generate evidence and support patient research.
  • Growing data landscape: More so than ever, respondents are using non-traditional data sources, such as purpose-built linked data, connected wearable technology, and health apps to drive decision making.
  • Shifting RWE activities in house: Seventy percent of respondents reported internally building out data analytics programs to gather and analyze RWE, driving an increase in RWE spending on talent and technology.
RWE in end-to-end evidence management3
  • Optimizing value: Applying RWE to develop, support, and sustain a compelling value story for approved therapeutic interventions and to inform new opportunities for therapeutic discovery.
  • Generating value: Leveraging RWE to maximize the potential for clinical and commercial success, optimize therapeutic response, and assess category dynamics to support pricing strategies.
  • Discovering value: Using RWE to enhance preclinical and clinical research productivity through precise target and patient cohort identification.

This newsletter is a periodic compilation of certain capital markets information. Information contained in this newsletter should not be construed as a recommendation to sell or a recommendation to buy any security. Any reference to or omission of any reference to any company in this newsletter shall not be construed as a recommendation to sell, buy or take any other action with respect to any security of any such company. We are not soliciting any action with respect to any security or company based on this newsletter. This newsletter is published solely for the general information of clients and friends of Deloitte Corporate Finance LLC. It does not take into account the particular investment objectives, financial situation, or needs of individual recipients. Certain transactions, including those involving early-stage companies, give rise to substantial risk and are not suitable for all investors. This newsletter is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Prediction of future events is inherently subject to both known risks, uncertainties and other factors that may cause actual results to vary materially. We are under no obligation to update the information contained in this newsletter. We and our affiliates and related entities, partners, principals, directors, and employees, including persons involved in the preparation or issuance of this newsletter, may from time to time have “long” and “short” positions in, and buy or sell, the securities, or derivatives (including options) thereof, of companies mentioned herein. The companies mentioned in this newsletter may be: (i) investment banking clients of Deloitte Corporate Finance LLC; or (ii) clients of Deloitte Financial Advisory Services LLP and its related entities. The decision to include any company for mention or discussion in this newsletter is wholly unrelated to any audit or other services that Deloitte Corporate Finance LLC may provide or to any audit services or any services that any of its affiliates or related entities may provide to such company. No part of this newsletter may be copied or duplicated in any form by any means, or redistributed without the prior written consent of Deloitte Corporate Finance LLC.

References

1 Deloitte Center for Health Solutions (DCHS). Mission Critical: Biopharma companies are accelerating real-world evidence adoption, investment, and application. June 2018.

2 Ibid.

3 Ibid.

Did you find this useful?